U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SEC File Number 0-30641
CUSIP Number 50172 A 10 4
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
[ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR
For Period Ended: September 30, 2000
---------------------------------
Nothing in this Form shall be construed to imply that the Commission has
verified any information contained herein.
---------------------------------
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates: N/A
---------------------------------
Part I - Registrant Information
---------------------------------
Full Name of Registrant: L.A.M. Pharmaceutical Corp.
Former Name if Applicable: N/A
Address of Principal Executive Office (Street and Number)
800 Sheppard Avenue West
Commercial Unit 1
City, State and Zip Code
North York, Ontario
Canada M3H 6B4
<PAGE>
---------------------------------
Part II - Rules 12b-25(b) and (c)
---------------------------------
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, or transition report or
portion thereof will be filed on or before the fifteenth calendar day following
the prescribed due date; or the subject quarterly report or transition report on
Form l0-Q or portion thereof will be filed on or before the fifth calendar day
following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
---------------------------------
Part III - Narrative
---------------------------------
State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K,
10-Q, or N-SAR, or the transition report or portion thereof could not be filed
within the prescribed time period.
The Company did not complete the preparation of its financial statements
for the quarter ending September 30, 2000 in sufficient time so as to permit the
filing of the 10-QSB report by November 14, 2000.
---------------------------------
Part IV - Other Information
---------------------------------
(1) Name and telephone number of person to contact in regard to this
notification
William T. Hart (303) 839-0061
----------------- ----- --------
(Name) (Area Code) (Telephone Number)
<PAGE>
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding l2 months (or
for such shorter period that the registrant was required to file such
reports) been filed? If answer is no, identify
report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or
portion thereof? [ ] Yes [X] No
If so: attach an explanation of the anticipated change, both
narrative-ly and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
L.A.M. Pharmaceutical Corp.
----- ----------------------------
(Name of Registrant as specified in charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: November 14, 2000 By
----------------------------------------
Alan Drizen, Chief Executive Officer
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).
